000131492 001__ 131492
000131492 005__ 20241125101156.0
000131492 0247_ $$2doi$$a10.1038/s41598-023-43287-4
000131492 0248_ $$2sideral$$a136836
000131492 037__ $$aART-2023-136836
000131492 041__ $$aeng
000131492 100__ $$aJonaitis, Paulius
000131492 245__ $$aComparison of the management of Helicobacter pylori infection between the older and younger European populations
000131492 260__ $$c2023
000131492 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131492 5203_ $$aThe prevalence of Helicobacter pylori remains high in the older population. Specific age-related peculiarities may impact the outcomes of H. pylori treatment. The aim of the study was to evaluate the diagnostics and effectiveness of H. pylori eradication between the younger and older European populations. “European Registry on H. pylori Management (Hp-EuReg)” data from 2013 to 2022 were analyzed. Patients were divided into older (≥ 60 years) and younger (18–59 years) groups. Modified intention-to-treat (mITT) and per-protocol (PP) analysis was performed. 49,461 patients included of which 14,467 (29%) were older-aged. Concomitant medications and penicillin allergy were more frequent among the older patients. Differences between younger and older populations were observed in treatment duration in first-line treatment and in proton pump inhibitors (PPIs) doses in second-line treatment. The overall incidence of adverse events was lower in the older adults group. The overall first-line treatment mITT effectiveness was 88% in younger and 90% in the older patients (p < 0.05). The overall second-line mITT treatment effectiveness was 84% in both groups. The effectiveness of the most frequent first- and second-line triple therapies was suboptimal (< 90%) in both groups. Optimal efficacy (≥ 90%) was achieved by using bismuth and non-bismuth-based quadruple therapies. In conclusion, the approach to the diagnostics and treatment of H. pylori infection did not generally differ between younger and older patients. Main differences were reported in the concurrent medications, allergy to penicillin and adverse events both in first- and second-line treatment. Optimal effectiveness rates were mostly achieved by using bismuth and non-bismuth-based quadruple therapies. No clinically relevant differences in the effectiveness between the age groups were observed.
000131492 536__ $$9info:eu-repo/grantAgreement/EC/HORIZON EUROPE/101095359/EU/An Artificially Intelligent Diagnostic Assistant for gastric inflammation/AIDA
000131492 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131492 590__ $$a3.8$$b2023
000131492 592__ $$a0.9$$b2023
000131492 591__ $$aMULTIDISCIPLINARY SCIENCES$$b25 / 134 = 0.187$$c2023$$dQ1$$eT1
000131492 593__ $$aMultidisciplinary$$c2023$$dQ1
000131492 594__ $$a7.5$$b2023
000131492 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131492 700__ $$aNyssen, Olga P.
000131492 700__ $$aSaracino, Ilaria Maria
000131492 700__ $$aFiorini, Giulia
000131492 700__ $$aVaira, Dino
000131492 700__ $$aPérez-Aísa, Ángeles
000131492 700__ $$aTepes, Bojan
000131492 700__ $$aCastro-Fernandez, Manuel
000131492 700__ $$aPabón-Carrasco, Manuel
000131492 700__ $$aKeco-Huerga, Alma
000131492 700__ $$aVoynovan, Irina
000131492 700__ $$aLucendo, Alfredo J.
000131492 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000131492 700__ $$aMartínez Domínguez, Samuel J.$$uUniversidad de Zaragoza
000131492 700__ $$aAlfaro Almajano, Enrique$$uUniversidad de Zaragoza
000131492 700__ $$aRodrigo, Luis
000131492 700__ $$aVologzanina, Ludmila
000131492 700__ $$aBrglez Jurecic, Natasa
000131492 700__ $$aDenkovski, Maja
000131492 700__ $$aBujanda, Luis
000131492 700__ $$aMahmudov, Umud
000131492 700__ $$aLeja, Marcis
000131492 700__ $$aLerang, Frode
000131492 700__ $$aBabayeva, Gülüstan
000131492 700__ $$aBordin, Dmitry S.
000131492 700__ $$aGasbarrini, Antonio
000131492 700__ $$aKupcinskas, Juozas
000131492 700__ $$aGridnyev, Oleksiy
000131492 700__ $$aRokkas, Theodore
000131492 700__ $$aMarcos-Pinto, Ricardo
000131492 700__ $$aPhull, Perminder S.
000131492 700__ $$aSmith, Sinead M.
000131492 700__ $$aTonkic, Ante
000131492 700__ $$aBoltin, Doron
000131492 700__ $$aBuzás, György Miklós
000131492 700__ $$aŠembera, Štepán
000131492 700__ $$aSimsek, Halis
000131492 700__ $$aMatysiak-Budnik, Tamara
000131492 700__ $$aMilivojevic, Vladimir
000131492 700__ $$aMarlicz, Wojciech
000131492 700__ $$aVenerito, Marino
000131492 700__ $$aBoyanova, Lyudmila
000131492 700__ $$aDoulberis, Michael
000131492 700__ $$aCapelle, Lisette G.
000131492 700__ $$aCano-Català, Anna
000131492 700__ $$aMoreira, Leticia
000131492 700__ $$aMégraud, Francis
000131492 700__ $$aO’Morain, Colm
000131492 700__ $$aGisbert, Javier P.
000131492 700__ $$aJonaitis, Laimas
000131492 700__ $$aBumane, Renate
000131492 700__ $$aMammadov, Emin
000131492 700__ $$aAbdulkhakov, Rustam A.
000131492 700__ $$aFadeenko, Galina
000131492 700__ $$aHuguet, Jose M.
000131492 700__ $$a
000131492 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131492 773__ $$g13 (2023), 17235 [13 pp.]$$pSci. rep. (Nat. Publ. Group)$$tScientific reports (Nature Publishing Group)$$x2045-2322
000131492 8564_ $$s2309751$$uhttps://zaguan.unizar.es/record/131492/files/texto_completo.pdf$$yVersión publicada
000131492 8564_ $$s2485332$$uhttps://zaguan.unizar.es/record/131492/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131492 909CO $$ooai:zaguan.unizar.es:131492$$particulos$$pdriver
000131492 951__ $$a2024-11-22-12:09:08
000131492 980__ $$aARTICLE